A registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Rigosertib (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 16 Aug 2023 New trial record
- 10 Aug 2023 According to an Onconova Therapeutics media release, based on a constructive Type B FDA meeting held in June, the company has planned to design this registrational trial and will look to provide an update on next steps in H1 2024.